TSTickerStarGet alerts

SKYE 10-Q filed 2026-11-13 | Key takeaways

SKYE filed its 10-Q; the most relevant disclosure change is added Reverse Stock Split: The company completed a 1-for-8 reverse stock split effective August 24, 2026, reducing authorized shares from 300,000,000 to 37,500,000. No fractional shares were issued; stockholders received cash in lieu thereof.

Share this story

Key takeaways

  • Reverse stock split: A 1-for-8 reverse stock split was completed effective August 24, 2026, reducing authorized shares from 300,000,000 to 37,500,000.

  • Pending Redx acquisition: On August 14, 2026, Skye entered into a Transaction Agreement to acquire Redx Pharma Limited via a scheme of arrangement under UK law, with concurrent financing of up to $72.9 million.

  • Cunning Lawsuit resolved: A November 10, 2026 jury returned a unanimous verdict in favor of the Company on all claims, resulting in a $5.0 million reduction in legal contingency reserves in Q3 2026.

  • Securities class action settlement: The company reached a $2.5 million settlement in the Stout v. Skye Bioscience securities class action, expected to be funded by insurance carriers.

  • Material weakness: Management identified a material weakness in controls over stock-based compensation expense related to award data from the third-party stock administration service provider.

  • R&D expenses declined 86% in Q3: Research and development expenses fell to $1.3 million from $9.4 million year-over-year following termination of the CBeyond trial and pausing of nimacimab R&D activities.

  • Nasdaq compliance: The company received a Nasdaq notification regarding its $1.36 million stockholders' equity not meeting the $2.5 million minimum requirement and submitted a compliance plan.

Key metrics

Net income (loss) - Q3Q3 2026
$69,126$12,823,786 improvement
Net income (loss) - YTDYTD 2026
($23,226,829)$18,256,022 improvement
Basic EPS - Q3Q3 2026
$0.01$2.58 improvement
Diluted EPS - Q3Q3 2026
$0.01$2.58 improvement
Basic EPS - YTDYTD 2026
($4.68)$3.69 improvement
Diluted EPS - YTDYTD 2026
($4.68)$3.69 improvement
Research and development expenses - Q3Q3 2026
$1,316,222($8,041,222) or (86)%
Research and development expenses - YTDYTD 2026
$13,193,834($17,698,620) or (57)%

Disclosure changes

  • Reverse Stock Split

    The company completed a 1-for-8 reverse stock split effective August 24, 2026, reducing authorized shares from 300,000,000 to 37,500,000. No fractional shares were issued; stockholders received cash in lieu thereof.

    Reverse stock split significantly reduced share count and increased per-share metrics; common stock par value remained $0.001 per share
  • Pending Redx Transaction and Related Financings

    On August 14, 2026, Skye entered into a Transaction Agreement to acquire Redx Pharma Limited via a scheme of arrangement. Concurrently, Redx completed a $36.0 million Series A Financing and Skye entered into a PIPE Securities Purchase Agreement for up to $72.9 million and an ELOC with Redmile for up to $22.0 million.

    Major M&A transaction that will fundamentally change the company's business, leadership, and name to Fibrx Therapeutics
  • Cunning Lawsuit and Legal Contingency Reversal

    On November 10, 2026, a jury returned a unanimous verdict in favor of the Company on all claims in the Cunning Lawsuit retrial. As of September 30, 2026, the estimated legal contingency is $0 (excluding accrued legal expenses of $222,839), resulting in a $5.0 million reduction in Q3 2026.

    Complete reversal of previously recorded legal contingency; $5.0 million credit to income in Q3 2026
  • Securities Class Action Settlement

    On November 6, 2026, the parties in the Stout v. Skye Bioscience securities class action entered into a settlement stipulation providing for an aggregate cash payment of $2.5 million, to be funded by insurance carriers, subject to court approval.

    Settlement resolves pending securities class action without admission of liability
  • Material Weakness in Internal Control

    Management identified a material weakness in controls over stock-based compensation expense, specifically inadequate review controls to verify completeness and accuracy of award data and calculations from the third-party stock administration service provider, including changes for employee terminations and award expirations.

    Material weakness indicates control deficiency that could result in misstatement of financial statements; remediation plan in progress
  • Halozyme License Agreement Termination

    On August 11, 2026, the Company notified Halozyme of its intent to terminate the Halozyme License Agreement for ENHANZE drug delivery technology.

    Termination of license agreement reflects company's strategic shift away from nimacimab development

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow SKYE in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert